Table 1. Patient characteristics .... | American Society of Hematology

Table 1.

Patient characteristics

	Initial phase	%	Phase 1	%	Phase 2	%	Phase 3	%	Phase 4	%	MRD phase	%
Number	69		61		28		78		83		178
Age, y
Median	6		5		5		5		3		5
Minimum	0		1		1		0		0		0
Maximum	76		75		17		17		55		77
Sex
Male	35	56	40	66	14	50	46	59	43	52	94	53
Female	27	44	21	34	14	50	32	41	40	48	84	47
White blood cell count (×10⁹/L)
Median	13.4		8.2		13.7		10.9		15.9		8.5
Minimum	0.4		0.8		1.2		0.7		0.5		0.5
Maximum	818		87.6		312		595		1250		900
No data	10		1		0		2		19		11
Immunophenotype
Pro-B-ALL	8	13	2	3	4	14	5	6	6	7	5	3
Common-ALL	44	73	48	79	20	71	59	76	56	67	137	77
Pre-B-ALL	8	13	11	18	4	14	13	17	21	25	35	20
No data	7		0		0		1		0		1
Genetic data*
TEL-AML1	6	11	15	27	6	27	11	16	11	18	45	26
BCR-ABL	4	6	1	2	0	0	3	4	1	2	4	2
E2A-PBX1	0	0	3	6	0	0	0	0	0	0	4	2
MLL-AF4	4	6	1	2	2	7	3	4	4	6	3	2
MLL other	2	3	1	2	1	4	1	1	1	2	2	1
Hyperdiplod	14	25	27	48	6	26	26	37	22	37	67	43
Hypodiploid	0	0	1	2	1	4	1	1	1	2	2	1

	Initial phase	%	Phase 1	%	Phase 2	%	Phase 3	%	Phase 4	%	MRD phase	%
Number	69		61		28		78		83		178
Age, y
Median	6		5		5		5		3		5
Minimum	0		1		1		0		0		0
Maximum	76		75		17		17		55		77
Sex
Male	35	56	40	66	14	50	46	59	43	52	94	53
Female	27	44	21	34	14	50	32	41	40	48	84	47
White blood cell count (×10⁹/L)
Median	13.4		8.2		13.7		10.9		15.9		8.5
Minimum	0.4		0.8		1.2		0.7		0.5		0.5
Maximum	818		87.6		312		595		1250		900
No data	10		1		0		2		19		11
Immunophenotype
Pro-B-ALL	8	13	2	3	4	14	5	6	6	7	5	3
Common-ALL	44	73	48	79	20	71	59	76	56	67	137	77
Pre-B-ALL	8	13	11	18	4	14	13	17	21	25	35	20
No data	7		0		0		1		0		1
Genetic data*
TEL-AML1	6	11	15	27	6	27	11	16	11	18	45	26
BCR-ABL	4	6	1	2	0	0	3	4	1	2	4	2
E2A-PBX1	0	0	3	6	0	0	0	0	0	0	4	2
MLL-AF4	4	6	1	2	2	7	3	4	4	6	3	2
MLL other	2	3	1	2	1	4	1	1	1	2	2	1
Hyperdiplod	14	25	27	48	6	26	26	37	22	37	67	43
Hypodiploid	0	0	1	2	1	4	1	1	1	2	2	1

Genetic data were not available for all patients; percentages refer to positive patients per all analyzed patients.